$0.88
0.89% yesterday
Nasdaq, Sep 24, 10:15 pm CET
ISIN
US4525EP1011
Symbol
IMUX

Immunic, Inc. Stock price

$0.88
+0.00 0.26% 1M
-0.29 24.86% 6M
-0.12 12.09% YTD
-0.68 43.65% 1Y
-2.12 70.70% 3Y
-14.76 94.38% 5Y
-188.32 99.54% 10Y
-479.12 99.82% 20Y
Nasdaq, Closing price Wed, Sep 24 2025
-0.01 0.89%
ISIN
US4525EP1011
Symbol
IMUX
Industry

Key metrics

Basic
Market capitalization
$86.7m
Enterprise Value
$31.4m
Net debt
positive
Cash
$55.3m
Shares outstanding
98.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.6
Financial Health
Equity Ratio
45.1%
Return on Equity
-545.4%
ROCE
-308.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-105.1m | -
EBIT
$-105.3m | $-100.9m
Net Income
$-101.8m | $-71.6m
Free Cash Flow
$-90.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-12.4% | -
EBIT
-12.4% | -2.9%
Net Income
-6.9% | 28.7%
Free Cash Flow
-24.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.8
FCF per Share
$-0.9
Short interest
10.2%
Employees
90
Rev per Employee
$0.0
Show more

Is Immunic, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Immunic, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Immunic, Inc. forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Immunic, Inc. forecast:

Buy
92%
Hold
8%

Financial data from Immunic, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
11% 11%
-
- Research and Development Expense 86 86
13% 13%
-
-105 -105
12% 12%
-
- Depreciation and Amortization 0.16 0.16
33% 33%
-
EBIT (Operating Income) EBIT -105 -105
12% 12%
-
Net Profit -102 -102
7% 7%
-

In millions USD.

Don't miss a Thing! We will send you all news about Immunic, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunic, Inc. Stock News

Neutral
PRNewsWire
about one hour ago
– Vidofludimus Calcium Demonstrated Statistically Significant 24-Week Confirmed Disability Improvement in Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis, With Over Two-Fold Probability Over Placebo in the Overall Study Population and Consistent Effects Across Subtypes – – CALLIPER Data Showed Positive and Consistent Signals for Slowing Disability Progression Across Disability Endpoint...
Positive
Proactive Investors
16 days ago
Immunic Inc (NASDAQ:IMUX) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) covering dose strengths of its lead asset, vidofludimus calcium (IMU-838), for the treatment of progressive multiple sclerosis (PMS). The patent, tied to application 18/529,946, protects daily dosing of about 10 mg to 45 mg of vidofludimus calcium, including ...
More Immunic, Inc. News

Company Profile

Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.

Head office United States
CEO Daniel Vitt
Employees 90
Founded 2003
Website imux.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today